Drug intelligence / Profile preview

VC005 + probenecid

Development stage: Unknown
Lead developer: Jiangsu Vcare Pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

VC005 + probenecid is an investigational drug combination evaluated in a Phase I drug-drug interaction (DDI) study in healthy adult subjects. VC005 is a novel, potent, and highly selective second-generation small molecule Janus kinase 1 (JAK1) inhibitor developed by Jiangsu Vcare PharmaTech Co., Ltd. (with exclusive commercialization rights in mainland China held by Huadong Medicine). It is being developed for multiple autoimmune and inflammatory diseases, including atopic dermatitis, ankylosing spondylitis, vitiligo, rheumatoid arthritis, and inflammatory bowel disease. Probenecid is a well-known inhibitor of organic anion transporters (OAT) and is used as a probe drug in this DDI study to evaluate the pharmacokinetic interactions and the role of OAT transporters in the clearance of VC005.

Other names: VC-005 + probenecid

Targets

TYK2 (Tyrosine kinase 2)JAK2 (Janus kinase 2)SLC22A8 (Organic anion transporter 3)JAK1 (Janus kinase 1)JAK3 (Janus kinase 3)OAT1 (Organic anion transporter 1)

Beyond the preview

Go deeper on VC005 + probenecid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VC005 + probenecid.

Explore the full profile